{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:36Z","timestamp":1740120096175,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma AG, Basel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12185-022-03311-1","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T06:02:45Z","timestamp":1645768965000},"page":"704-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan"],"prefix":"10.1007","volume":"115","author":[{"given":"Wen-Li","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsuan-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ching","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyh-Pyng","family":"Gau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Shou","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Ming","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan-Chen","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-3281","authenticated-orcid":false,"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"3311_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF01630378","volume":"8","author":"PC Nowell","year":"1962","unstructured":"Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut. 1962;8:65\u20136.","journal-title":"Blut"},{"key":"3311_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"3311_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765\u20137.","journal-title":"Nature"},{"key":"3311_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"3311_CR5","unstructured":"Novartis Pharmaceuticals Corporation: East Hanover N, USA. Tasigna. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/tasigna.pdf?site=PC001536&irmasrc=NA&source=01030. Accessed  Sep 2021."},{"key":"3311_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"3311_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD le Coutre","year":"2012","unstructured":"le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012;26:1189\u201394.","journal-title":"Leukemia"},{"key":"3311_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"3311_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"3311_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620718756603","volume":"9","author":"CY Kuo","year":"2018","unstructured":"Kuo CY, Wang PN, Hwang WL, Tzeng CH, Bai LY, Tang JL, et al. Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. Ther Adv Hematol. 2018;9:65\u201378.","journal-title":"Ther Adv Hematol"},{"key":"3311_CR11","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30:4323\u20139.","journal-title":"J Clin Oncol"},{"key":"3311_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353\u201360.","journal-title":"Blood"},{"key":"3311_CR13","unstructured":"Summary of product characteristics for Tasigna. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_en.pdf. Accessed  Sep 2021."},{"key":"3311_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57\u201364.","journal-title":"Leukemia"},{"key":"3311_CR15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197\u2013203.","journal-title":"Leukemia"},{"key":"3311_CR16","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771\u20138.","journal-title":"Blood"},{"key":"3311_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-2-46","volume":"2","author":"D Masiello","year":"2009","unstructured":"Masiello D, Gorospe G 3rd, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol. 2009;2:46.","journal-title":"J Hematol Oncol"},{"key":"3311_CR18","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009;114:4933\u20138.","journal-title":"Blood"},{"key":"3311_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0002-9343(49)90173-4","volume":"6","author":"AJ Merrill","year":"1949","unstructured":"Merrill AJ. Mechanisms of salt and water retention in heart failure. Am J Med. 1949;6:357\u201367.","journal-title":"Am J Med"},{"key":"3311_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337\u201340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3311_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000468510","volume":"11","author":"V Patel","year":"2017","unstructured":"Patel V, Pattisapu A, Attia K, Weiss J. Nilotinib-induced acute pancreatitis in a patient with chronic myeloid leukemia. Case Rep Gastroenterol. 2017;11:344\u20137.","journal-title":"Case Rep Gastroenterol"},{"key":"3311_CR22","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.2169\/internalmedicine.55.7104","volume":"55","author":"T Yamada","year":"2016","unstructured":"Yamada T, Nannya Y, Shimizu M, Seishima M, Tsurumi H. Symptomatic acute pancreatitis induced by nilotinib: a report of two cases. Intern Med. 2016;55:3495\u20137.","journal-title":"Intern Med"},{"key":"3311_CR23","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310\u20135.","journal-title":"Leukemia"},{"key":"3311_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316\u201321.","journal-title":"Leukemia"},{"key":"3311_CR25","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"3311_CR26","unstructured":"Livertox: clinical and research information on drug-induced liver injury. bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/"},{"key":"3311_CR27","doi-asserted-by":"publisher","first-page":"e00003-e","DOI":"10.14309\/crj.0000000000000003","volume":"6","author":"Y Belopolsky","year":"2019","unstructured":"Belopolsky Y, Grinblatt DL, Dunnenberger HM, Sabatini LM, Joseph NE, Fimmel CJ. A case of severe, nilotinib-induced liver injury. ACG Case Rep J. 2019;6:e00003-e.","journal-title":"ACG Case Rep J"},{"key":"3311_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3389\/fonc.2020.01160","volume":"10","author":"H Yang","year":"2020","unstructured":"Yang H, Sung PS, Jung ES, Cho S, Bae SH, Kim DW. Nilotinib-induced immune-mediated liver injury: corticosteroid as a possible therapeutic option. Front Oncol. 2020;10:1160.","journal-title":"Front Oncol"},{"key":"3311_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3109\/00498254.2013.840750","volume":"44","author":"L Ai","year":"2014","unstructured":"Ai L, Zhu L, Yang L, Ge G, Cao Y, Liu Y, et al. Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica. 2014;44:320\u20135.","journal-title":"Xenobiotica"},{"key":"3311_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","volume":"29","author":"M Abumiya","year":"2014","unstructured":"Abumiya M, Takahashi N, Niioka T, Kameoka Y, Fujishima N, Tagawa H, et al. Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia. Drug Metab Pharmacokinet. 2014;29:449\u201354.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3311_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.leukres.2014.09.016","volume":"38","author":"M Breccia","year":"2014","unstructured":"Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38:1392\u20138.","journal-title":"Leuk Res"},{"key":"3311_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","volume":"34","author":"M Franklin","year":"2018","unstructured":"Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. Curr Med Res Opin. 2018;34:353\u201360.","journal-title":"Curr Med Res Opin"},{"key":"3311_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","volume":"35","author":"M Tokuhira","year":"2018","unstructured":"Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, et al. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018;35:38.","journal-title":"Med Oncol"},{"key":"3311_CR34","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"3311_CR35","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"3311_CR36","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European leukemianet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03311-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:20:00Z","timestamp":1659097200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03311-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3311"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03311-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}